KR102308673B1 - 칼륨의 감소 및 만성 신장 및/또는 만성 심장 질환의 치료를 위한 미세다공성 규산지르코늄 및 이뇨제 - Google Patents

칼륨의 감소 및 만성 신장 및/또는 만성 심장 질환의 치료를 위한 미세다공성 규산지르코늄 및 이뇨제 Download PDF

Info

Publication number
KR102308673B1
KR102308673B1 KR1020157031787A KR20157031787A KR102308673B1 KR 102308673 B1 KR102308673 B1 KR 102308673B1 KR 1020157031787 A KR1020157031787 A KR 1020157031787A KR 20157031787 A KR20157031787 A KR 20157031787A KR 102308673 B1 KR102308673 B1 KR 102308673B1
Authority
KR
South Korea
Prior art keywords
delete delete
potassium
dose
treatment
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157031787A
Other languages
English (en)
Korean (ko)
Other versions
KR20150140750A (ko
Inventor
도날드 제프리 카이저
알바로 에프. 길렘
Original Assignee
제트에스 파마, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51654632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102308673(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제트에스 파마, 인코포레이티드 filed Critical 제트에스 파마, 인코포레이티드
Publication of KR20150140750A publication Critical patent/KR20150140750A/ko
Application granted granted Critical
Publication of KR102308673B1 publication Critical patent/KR102308673B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157031787A 2013-04-05 2014-04-03 칼륨의 감소 및 만성 신장 및/또는 만성 심장 질환의 치료를 위한 미세다공성 규산지르코늄 및 이뇨제 Active KR102308673B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361808897P 2013-04-05 2013-04-05
US61/808,897 2013-04-05
US201361914362P 2013-12-10 2013-12-10
US61/914,362 2013-12-10
US201461930331P 2014-01-22 2014-01-22
US61/930,331 2014-01-22
PCT/US2014/032815 WO2014165670A1 (en) 2013-04-05 2014-04-03 Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

Publications (2)

Publication Number Publication Date
KR20150140750A KR20150140750A (ko) 2015-12-16
KR102308673B1 true KR102308673B1 (ko) 2021-10-01

Family

ID=51654632

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157031787A Active KR102308673B1 (ko) 2013-04-05 2014-04-03 칼륨의 감소 및 만성 신장 및/또는 만성 심장 질환의 치료를 위한 미세다공성 규산지르코늄 및 이뇨제

Country Status (21)

Country Link
US (3) US20140302175A1 (enExample)
EP (1) EP2981272B1 (enExample)
JP (1) JP6280636B2 (enExample)
KR (1) KR102308673B1 (enExample)
CN (1) CN105473151B (enExample)
AU (1) AU2014248081B2 (enExample)
BR (1) BR112015025438B1 (enExample)
CA (1) CA2908641C (enExample)
CL (1) CL2015002951A1 (enExample)
DK (1) DK2981272T3 (enExample)
ES (1) ES2943007T3 (enExample)
FI (1) FI2981272T3 (enExample)
HU (1) HUE061862T2 (enExample)
IL (1) IL241926B (enExample)
MX (1) MX2015014055A (enExample)
PH (1) PH12015502301A1 (enExample)
PL (1) PL2981272T3 (enExample)
PT (1) PT2981272T (enExample)
TW (1) TW201521746A (enExample)
WO (1) WO2014165670A1 (enExample)
ZA (1) ZA201507666B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900037T1 (it) 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
CN114917247B (zh) * 2022-05-18 2024-01-26 广东省疾病预防控制中心 纳米二氧化钛在防治肾损伤中的应用
CN117776193A (zh) * 2023-12-25 2024-03-29 杭州国瑞生物科技有限公司 一种环硅酸锆钠zs-9的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159505A (en) 1996-01-24 2000-12-12 Piper; Edwina M. Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20120213847A1 (en) * 2011-02-11 2012-08-23 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
EP1307270A1 (en) * 2000-07-12 2003-05-07 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
AU2002242103A1 (en) * 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) * 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
CN103919792B (zh) 2008-08-22 2018-03-09 瑞立普萨公司 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
MX2015000381A (es) * 2012-07-11 2015-11-23 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
KR102184602B1 (ko) * 2012-10-22 2020-11-30 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159505A (en) 1996-01-24 2000-12-12 Piper; Edwina M. Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20120213847A1 (en) * 2011-02-11 2012-08-23 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia

Also Published As

Publication number Publication date
JP6280636B2 (ja) 2018-02-14
CA2908641C (en) 2022-10-18
EP2981272A1 (en) 2016-02-10
IL241926B (en) 2020-10-29
AU2014248081B2 (en) 2019-02-28
MX2015014055A (es) 2015-12-15
CL2015002951A1 (es) 2016-11-11
FI2981272T3 (fi) 2023-05-03
HUE061862T2 (hu) 2023-08-28
EP2981272A4 (en) 2016-12-07
WO2014165670A1 (en) 2014-10-09
EP2981272B1 (en) 2023-03-01
KR20150140750A (ko) 2015-12-16
US20140302175A1 (en) 2014-10-09
CN105473151B (zh) 2018-09-18
DK2981272T3 (da) 2023-05-01
US10695366B2 (en) 2020-06-30
BR112015025438B1 (pt) 2022-06-07
JP2016515624A (ja) 2016-05-30
HK1221177A1 (en) 2017-05-26
AU2014248081A1 (en) 2015-11-12
PH12015502301A1 (en) 2016-02-10
US20180271902A1 (en) 2018-09-27
ES2943007T3 (es) 2023-06-08
CN105473151A (zh) 2016-04-06
CA2908641A1 (en) 2014-10-09
PL2981272T3 (pl) 2023-05-29
ZA201507666B (en) 2019-09-25
PT2981272T (pt) 2023-05-03
BR112015025438A2 (pt) 2017-07-18
TW201521746A (zh) 2015-06-16
US20160051584A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
KR102332954B1 (ko) 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄
AU2017251722A1 (en) Microporous zirconium silicate for treating hyperkalemia
US20160375054A1 (en) Microporous Zirconium Silicate for the Treatment of Hyperkalemia
US10695366B2 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
US20160038538A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
US20150359821A1 (en) Microporous Zirconium Silicate for the Treatment of Hyperkalemia
KR20160096178A (ko) 리튬 공동 투여 없이 고칼륨혈증을 치료하기 위한 규산지르코늄
HK40112785A (en) Microporous zirconium silicate for the treatment of hyperkalemia
HK1221177B (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
HK1231745A1 (zh) 用於治疗高钾血症的微孔硅酸锆
HK1231745B (zh) 用於治疗高钾血症的微孔硅酸锆

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151105

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190319

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200706

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210107

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210601

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210107

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200706

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210601

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210219

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200826

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151116

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210702

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210621

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210601

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210219

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200826

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151116

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210928

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210928

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240823

Start annual number: 4

End annual number: 4